Roivant posts lower than expected Q2 operating loss on lower R&D espenses

By Reuters News


Overview

  • Switzerland biopharma's Q2 net product revenue was $31.0 mln, driven by LISRAYA launch

  • Income from operations for Q2 beat analyst expectations

  • Company repurchased 2.1 mln shares for $72.5 mln during the quarter


Outlook

  • Roivant expects cash runway into profitability, supported by $4.2 bln cash as of Sept 30, 2026

  • Company plans sNDA filing for brepocitinib in NIU in H1 2027

  • Immunovant to meet with FDA in 2026 on IMVT-1402 registrational path in D2T RA


Result Drivers

  • LISRAYA LAUNCH - Q2 revenue driven by $31.0 mln in net product revenue from LISRAYA's first 5 weeks on the market, reflecting early patient and prescriber demand, per CEO Matt Gline

  • HIGHER SG&A COSTS - Selling, general and administrative expenses rose $11.0 mln year-over-year, mainly due to costs related to the commercial launch of LISRAYA

  • LOWER R&D EXPENSES - R&D expenses fell $18.8 mln year-over-year, mainly due to reduced personnel and program-specific costs, including lower spending on discontinued and winding-down studies


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Revenue

$30.97 mln

Q2 Net Loss

$137.21 mln

Q2 Income From Operations

Beat

-$268.05 mln

-$336.33 mln (10 Analysts)

Q2 Loss Per Basic Share

$0.27

Q2 Operating Expenses

$303.17 mln


Reuters Recommended Reads

  • Nov 6 - CG Oncology Q3 net loss widens on higher R&D costs

  • Nov 7 - Trial failures of Novartis, Novo Nordisk heart drugs leave experts guessing

  • Nov 6 - Minerva Neurosciences posts Q3 profit on non-cash warrant gain


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.